SOURCE: Dynavax Technologies

Dynavax Technologies

September 16, 2011 09:00 ET

Dynavax to Present at the UBS Global Life Sciences Conference

BERKELEY, CA--(Marketwire - Sep 16, 2011) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 3:30 pm EDT (12:30 pm PDT).

Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will provide a corporate overview presentation. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit

Contact Information

  • Contact:
    Shari Annes
    Investor Relations
    Email Contact